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Purpose: Persistent idiopathic facial pain (PIFP) is a poorly defined and debilitating chronic
pain state with a challenging and often inadequate treatment course. This is the first case report
identifying the novel use of low-dose lumbar intrathecal ziconotide to successfully treat PIFP
with nearly complete resolution of pain and minimal to no side effects.
Methods: The patient was a 37 year-old female whose PIFP was refractory to multimodal
medication management and multiple neurovascular surgical interventions. A single-shot
lumbar intrathecal trial of ziconotide (2.5 mL, equivalent 2.5 μg) was injected when she was at
her baseline pain level — VAS 7/10. She received complete resolution of her pain for about 9
hours, concordant with ziconotide’s half-life. She was subsequently implanted with a lumbar
intrathecal delivery system.
Results: The patient experienced complete resolution of her facial pain with a single-shot
intrathecal trial of ziconotide. The intrathecal pump system has provided nearly complete (VAS
1/10) pain relief. Two flares of pain occurred 10 and 18 months after pump placement, which
subsequently resolved after increasing the ziconotide dose by 0.5 μg/day on each occasion. The
patient is currently maintained on a dose of 2.0 μg/day and is pain-free.
Conclusion: This is the first case report describing the use of a single-shot lumbar intrathecal
trial of ziconotide and subsequent placement of lumbar (as opposed to thoracic) intrathecal
ziconotide pump for PIFP. A single-injection intrathecal trial is a low-risk, viable option for
patients with this debilitating and frustrating pain condition. Successful trials and subsequent
intrathecal pump placement with ziconotide may supplant multimodal medication management
and/or invasive orofacial surgical intervention for PIFP.
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Persistent idiopathic facial pain (PIFP), often previously referred to as atypical FP, is
a form of excruciating and debilitating neuropathic FP. It is likely an underdiagnosed
condition and has a poor prognosis.1 The estimated lifetime prevalence of PIFP is
approximately 0.03%, incidence 4.4 per 100,000 person years, and women in their
40s are most likely to suffer from the condition.1–3 Patients with PIFP may represent
approximately 10%–21% of the population of orofacial pain clinics.4,5
The International Headache Society has described PIFP as “persistent facial and/
or oral pain, with varying presentations but recurring daily for more than 2 hours per
day over more than 3 months, in the absence of clinical neurological deficit.”6 The
guidelines describe the pain as primarily dull, aching, or nagging, and the pain does
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not follow a peripheral nerve distribution. Most patients
present with poorly localizable, debilitating pain along the
distribution of the trigeminal nerve that does not follow a
dermatomal distribution and is typically without periods of
remission.1 The pain ranges from dull to sharp, can be bilateral or unilateral, and engages various locations on the face.
The diagnosis of PIFP is challenging to make. Diagnosis
is often one of exclusion. Due to the debilitating nature of
the disorder and absence of effective treatments, patients
with PIFP often seek treatment from clinicians of multiple
disciplines, most commonly including pain specialists, otolaryngologists, dentists, neurologists, neurosurgeons, and
psychiatrists.7
At this point, there are no curative therapies for PIFP.
A relatively limited number of pharmacological, nonpharmacological, and interventional treatment modalities have
been found to be moderately effective in the treatment of
PIFP. Pharmacologic treatments include topical analgesics
(lidocaine cream, capsaicin), botulinum-toxin injections, lowdose tricyclic antidepressants, selective serotonin-reuptake
inhibitors, serotonin–norepinephrine-reuptake inhibitors,
anticonvulsants, and opioids (tramadol or oxycodone).
Nonpharmacological treatment regimens include cognitive
behavior therapy (as an adjunct to antidepressant therapy),
pulsed-radiofrequency treatment, and peripheral nerve
stimulators.1
Ziconotide (Prialt; Jazz Pharmaceuticals, Dublin, Ireland), is a 25-amino-acid polybasic peptide present in the
venom of Conus magus, a marine snail.8 It selectively binds
to N-type voltage-gated calcium channels on neurons, which
are of particularly high density in the presynaptic terminals
of primary afferent neurons that ultimately terminate in the
dorsal horn of the spinal cord.9 Calcium influx is subsequently
disrupted and prevents release of neurotransmitters (such
as glutamate) and neuropeptides that are involved in pain
transmission.10–15
Intrathecal ziconotide has been used for chronic-pain
control in patients suffering from malignant and nonmalignant and AIDS-associated pain, and has had notable success
as a first-line monotherapy for intrathecal pump delivery.16–18
In this report, we describe the first case of using low-dose
lumbar administration of intrathecal ziconotide specifically
for PIFP.

Case report
Written informed consent was provided by the patient to have
this case published. Institutional approval was not required to
publish these case details. A 37-year-old woman was referred
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to the University of Pittsburgh Medical Center’s Center for
Brainstem and Cranial Nerve Disorders with bilateral FP having failed multiple treatments. The pain began as left-sided
dental pain in 2013. Although an etiology for her pain could
not be determined, she was given a diagnosis of “atypical
trigeminal neuralgia”. In 2016, she developed right-sided
FP of a similar quality and nature as her left-sided FP. She
described the pain as starting at her left ear and radiating
across her forehead, maxilla, and mandible.
The pain was exacerbated by “everything”, but specifically included snow, rain, wind, cold, hot liquids, spicy food
and crunchy food. The patient described her FP as starting
at her left ear with radiation across her forehead, maxilla,
and mandible and she rated it as 7/10 on a VAS. She did not
permit palpation of her face secondarily to the pain. She trialed and failed medical management, including pregabalin,
gabapentin, carbamazepine, phenytoin, levetiracetam, and
nortriptyline. She had undergone two prior microvascular
decompression surgeries that eliminated her pain for <2
weeks each time. She also underwent two glycerol rhizotomies with only short-lived relief. The patient denied a history
of oral surgeries or procedures other than a remote history
of wisdom-tooth extraction approximately 16 years prior to
the onset of pain.
After evaluation at our institution, a diagnosis of PIFP
was made. After discussion of all options with the patient,
including repeat injections, medication management, and cervicomedullary stimulator placement, the decision was made
to attempt a trial of intrathecal ziconotide in the lumbar spine
as a precursor to intrathecal pump placement. The patient
was evaluated by a psychologist and felt to be a reasonable
candidate for intrathecal pump treatment prior to the trial.
The patient’s medical history was unremarkable, other
than the FP and frontal headaches that occurred approximately three times weekly and were treated with hydrocodone/acetaminophen. She is a nonsmoker. Of note, she had
suffered post-dural puncture headaches with previous labor
epidurals.

Ziconotide trial
The patient was then given a single injection of 2.5 mL (2.5 μg
at 1 μg per mL) of intrathecal ziconotide at the L3–L4 level.
She remained in the recovery area following the injection for
observation. Within approximately 2 hours of the trial, the
patient had significant improvement in her VAS pain scores,
down from 7/10 prior to the injection to 2/10. Classic triggers
of her pain, such as drinking coffee or an ice pack on her face,
did not cause any worsening of her pain. No medication side
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effects, such as paranoia or hallucinations, were observed.
She was monitored for 6 hours after the injection, and her
pain remained approximately 2/10. The patient experienced
complete resolution of her pain for approximately 9 hours.
By postprocedure day 2, her FP had returned to her baseline
7/10 VAS. She developed transient symptoms of post-dural
puncture headache following discharge. The patient was
very satisfied with the trial and very interested in pursuing
an intrathecal pump of ziconotide.

Pump placement and follow-up
After the successful trial, the patient opted to proceed with
intrathecal pump placement. The epidural space was entered
in the lumbar cistern at approximately the L4–L5 level and
the intrathecal catheter advanced to 17 cm from the skin.
The patient’s recovery was significant for likely post-dural
puncture headache on postoperative day 3, as she described a
global headache that improved when she assumed the supine
position. She noted that this headache was different from her
baseline frontal headaches. She further noted resolution of
her FP to 0/10 VAS, as she had no baseline base and no pain
with activities that historically had exacerbated her pain. The
positional headache resolved on its own within approximately
1 week. About 1 month postoperatively, the patient went to
an outside hospital (given that she lived approximately 6
hours from the University of Pittsburgh Medical Center),
due to swelling at her left-lower-quadrant pump pocketinsertion site. The patient subsequently underwent surgical
reexploration with laminectomy to repair a cerebrospinal
fluid leak and pseudomeningocele, and was discharged home
shortly thereafter.
It has been approximately 22 months since intrathecal
pump placement. The patient was pain-free for approximately
10 months at a dose of 1.0 μg/day. She then experienced an
acute exacerbation of her pain, and the dose was increased to
1.5 μg/day. After the dose increase, she had little (VAS 1/10)
to no pain for approximately 8 additional months. She then
again had an acute worsening of her pain. The daily dose of
ziconotide was increased to 2.0 μg/day, and since then she
has remained pain-free with no notable side effects.

Discussion
The diagnosis of PIFP is appropriate when neuropathic
FP does not align with more common causes.1 Differential
diagnosis is extensive and spans a variety of organ systems:
musculoskeletal (temporomandibular disorder), odontogenic
(dental caries), neurovascular (trigeminal autonomic cephalgias), dermatological (Sjögren’s syndrome), neurological
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(varicella zoster/postherpetic neuralgia), and other etiologies.
Symptoms can be equally as vast and confusing, ranging
from hyperalgesia to hypoalgesia, allodynia to dysesthesia
to anesthesia, and intermittent to continuous pain, often with
no correlating image findings or causal agent.
Treatments for PIFP are increasingly promising
with modalities such as pulsed-radiofrequency ablation
of the sphenopalatine ganglion, peripheral nerve-field
stimulators, and botulinum toxin injections.1 Ziconotide, a
25-amino-acid polybasic peptide made from the venom of
Conus magus, a marine snail, selectively binds to N-type
voltage-gated calcium channels on neurons that block neurotransmission from primary afferent nociceptors.8 Intrathecal administration of ziconotide has had some efficacy
in chronic-pain patients, ranging from pain secondary to
nonmalignant conditions to cancer pain to refractory pain
in AIDS patients. There has also been some documentation of its use for neuropathically mediated FP, including
trigeminal neuralgia19,20 and a case series of three patients
with PIFP.21
The patient featured in this case report experienced temporary complete resolution of her FP with a single-injection
intrathecal trial and nearly complete resolution of pain with
intrathecal monotherapy via intrathecal pump administration. Ziconotide and morphine are the only two agents US
Food and Drug Administration-approved for intrathecal pain
management. Ziconotide is a hydrophilic molecule. This
accounts for the ability to administer it in the lumbar region,
yet patients are able to experience relief for FP without the
need for catheter-tip placement at the cervicomedullary junction.22 The exact mechanism by which intrathecal ziconotide
results in relief of idiopathic FP is not entirely clear. It has
been hypothesized that ziconotide can also exert some action
centrally in regions of the cerebrospinal fluid aqueduct, eg,
the caudate nucleus of the trigeminal nerve, with resultant
relief of trigeminal neuralgia.19
The 2017 Polyanalgesic Consensus Conference stated
that ziconotide was the first-line treatment for intrathecal
analgesia for chronic refractory pain.23 Additionally, current
data suggest that intrathecal ziconotide demonstrates greater
efficacy when ziconotide is the first monotherapy trialed.24
Pruzik et al were able to treat chronic pain effectively in 53%
of patients with intrathecal monotherapy of ziconotide as a
first-line intrathecal agent.18 The study utilized a low dose
and slow titration of ziconotide. Unlike morphine, intrathecal ziconotide can be stopped abruptly without concern
for withdrawal and is not associated with risk of respiratory depression. Pruzik et al did not note any withdrawal
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symptoms in their patients upon stopping the ziconotide
after 3 months of use.
Various dosing strategies of intrathecal ziconotide continue to be studied, but ziconotide has yet to be used as a
mainstream intrathecal medication for chronic pain, despite
not causing granulomas at the catheter site and providing
opioid-sparing treatment.25 The maximum daily dose of
intrathecal ziconotide has been described as 19.2 μg/day.26
Ziconotide is often cited for having a narrow therapeutic
window that can incite a number of adverse effects, including nausea, dizziness, diarrhea, peripheral edema, memory
impairment, asthenia, balance disorder, ataxia, abnormal
gait, fatigue, somnolence, urinary tract infection, headache,
vomiting, pain, increased creatine kinase, and pruritus.24,27
Psychiatric symptoms associated with ziconotide include
confusion (33%), memory impairment (22%), speech disorder (14%), hallucinations (12%), paranoid reactions (3%),
hostility (2%), delirium (2%), psychosis (1%), manic reactions (0.4%), aphasia (12%), abnormal thinking (8%), and
amnesia (1%).28 There are also data to support suicidality
being increased with ziconotide.29,30 To that end, it is contraindicated in patients with psychosis history. Adverse events
and serious adverse events were reported in 71.0% and 21.5%
of patients in an interim analysis of data from the PRIZM
study.24 Other studies have reported rates of adverse events of
57%–92.9%.31–33 Our patient did not experience any negative
side effects during either the ziconotide trial or since placement of the intrathecal pump. Despite its side-effect profile,
ziconotide appears to have great potential for the treatment
of chronic pain, including PIFP.
Ziconotide has been shown to have a volume of distribution equivalent to the total estimated cerebrospinal
fluid volume of approximately 140 mL.26 Therefore, even
low intrathecal infusion dosing strategies likely circulate
ziconotide from the lumbar intrathecal space to the cerebrospinal fluid surrounding brain and brain-stem tissue. In
a study of continuous intrathecal infusion rates of 0.1–7.0
μg/h in patients with chronic pain, a majority did not have
detectable plasma levels of ziconotide.26 No specific dose has
been delineated for when side effects become more likely.
The general tendency is to start with low infusion rates of
around 1.2 μg/day and uptitrate very slowly.18
To date, only one case series has documented the use
of intrathecal ziconotide specifically for PIFP.21 Lux and
Rasche documented doses of 2.4, 3.9, and 6.0 µg/day for
three patients that they treated for PIFP.21 Treatment was
stopped in one patient (2.4 µg/day dose) due to side effects.
The other two patients experienced reduction in their pain
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scores from numeric rating scale (NRS) 10 to NRS 4 and
NRS 9 to NRS 6.21 Our case study is different from Lux and
Rasche in a number of ways. We utilized a single-injection
trial instead of an external pump infusion trial, which has a
lower risk profile with regard to potential adverse effects. Our
patient’s intrathecal catheter was much lower in the spinal
column (lumbar cistern), rather than in the mid-thoracic
region, and finally our patient experienced complete resolution of her pain, both during the single-injection trial and
for approximately 10 months after pump placement at a low
dose (1.0 μg/day) of ziconotide. Our patient has required two
separate dose increases (0.5 µg/day each time), and at the
current dose (2.0 µg/day) remains pain- and side effect-free.
The patient has required two dose increases of ziconotide
since the placement of her intrathecal ziconotide pump. This
may raise the question of whether the patient is developing
a tolerance to ziconotide. This seems unlikely, as data from
other large registries and an open-label trial suggest the
absence of a tolerance effect.23,34,35 For example, Raffaeli et
al noted that patients that stayed in their study >6 months
were receiving stable doses of ziconotide, which may suggest
the absence of a tolerance effect.34 Deer et al documented
mean doses of 3.2 µg/day at 12 weeks and 1.9 µg/day at 12
months, further supporting the assertion that patients do not
develop tolerance.23

Conclusion
This is the first case report describing the use of a singleshot lumbar intrathecal trial of ziconotide and subsequent
placement of a lumbar intrathecal ziconotide pump for PIFP
with a protracted pain-free period after pump placement. A
single-injection intrathecal trial is a low-risk, viable option
for patients with this debilitating and frustrating pain condition. Successful trials and subsequent intrathecal pump
placement with use of ziconotide may supplant multimodal
medication management and/or invasive orofacial surgical
intervention for PIFP.
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